# Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America

> **NCT00084227** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 244 (actual)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **DRUG:** Azithromycin/Chloroquine
- **DRUG:** Atovaquone/Proguanil

## Key facts

- **NCT ID:** NCT00084227
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2011-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084227, "Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00084227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*